Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
Open Access
- 28 October 2018
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 24 (40) , 4606-4614
Abstract
To investigate survival rate and incidence of hepatocellular carcinoma (HCC) in patients with decompensated cirrhosis in the antiviral era. We used the Korean Health Insurance Review and Assessment. Korea's health insurance system is a public single-payer system. The study population consisted of 286871 patients who were prescribed hepatitis B antiviral therapy for the first time between 2007 and 2014 in accordance with the insurance guidelines. Overall, 48365 antiviral treatment-naïve patients treated between 2008 and 2009 were included, and each had a follow-up period ≥ 5 years. Data were analyzed for the 1st decompensated chronic hepatitis B (CHB) and treatment-naïve patients (n = 7166). The mean patient age was 43.5 years. The annual mortality rates were 2.4%-19.1%, and 5-year cumulative mortality rate was 32.6% in 1st decompensated CHB treatment-naïve subjects. But the annual mortality rates sharply decreased to 3.4% (2.4%-4.9%, 2-5 year) after one year of antiviral treatment. Incidence of HCC at first year was 14.3%, the annual incidence of HCC decreased to 2.5% (1.8%-3.7%, 2-5 year) after one year. 5-year cumulative incidence of HCC was 24.1%. Recurrence rate of decompensated event was 46.9% at first year, but the annual incidence of second decompensation events in decompensated CHB treatment-naïve patients was 3.4% (2.1%-5.4%, 2-5 year) after one year antiviral treatment. 5-year cumulative recurrence rate of decompensated events was 60.6%. Meanwhile, 5-year cumulative mortality rate was 3.1%, and 5-year cumulative incidence of HCC was 11.5% in compensated CHB treatment-naïve patients. Long term outcome of decompensated cirrhosis treated with antiviral agent improved much, and incidence of hepatocellular carcinoma and mortality sharply decreased after one year treatment.Keywords
This publication has 21 references indexed in Scilit:
- Long‐term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus–related cirrhosisHepatology, 2015
- Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs LamivudineGastroenterology, 2014
- Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysisThe Journal of Clinical Pharmacology, 2013
- Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysisWorld Journal of Gastroenterology, 2013
- Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionHepatology, 2012
- Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosisAlimentary Pharmacology & Therapeutics, 2012
- Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosisLiver International, 2010
- Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapyGastroenterology, 2002
- Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis BLiver Transplantation, 2002
- Occurrence of hepatocellular carcinoma and decompensation in western european patients with cirrhosis type BHepatology, 1995